| NCT ID | NCT06462274 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Southwest Hospital, China |
| Condition | Intracerebral Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2014-01-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2014-01-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged 18-80 years 2. Hematoma size is more than 5 ml 3. Evidence of a spontaneous ICH on CT scan 4. Patient within 72 hours of ictus 5. Glasgow Coma Scale (GCS) Score of 5-15. 6. The history of hypertension Exclusion Criteria: 1. Individuals with age \< 18 years or \> 80 years 2. Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases. 3. ICH secondary to tumor or trauma.. 4. If the haematological effects of any previous anticoagulants are not completely reversed. 5. Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.
Contact & Investigator
Rong Hu, Ph.D
PRINCIPAL INVESTIGATOR
Southwest Hospital, China
Frequently Asked Questions
Who can join the NCT06462274 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Intracerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06462274 currently recruiting?
Yes, NCT06462274 is actively recruiting participants. Contact the research team at huchrong@aliyun.com for enrollment information.
Where is the NCT06462274 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT06462274 clinical trial?
NCT06462274 is sponsored by Southwest Hospital, China. The principal investigator is Rong Hu, Ph.D at Southwest Hospital, China. The trial plans to enroll 200 participants.